Effectiveness of COVID-19 vaccination against COVID-19 specific and all-cause mortality in older Australians: a population based study

被引:12
|
作者
Liu, Bette [1 ,2 ]
Stepien, Sandrine [1 ]
Dobbins, Timothy [2 ,3 ]
Gidding, Heather [1 ,2 ,9 ]
Henry, David [2 ,3 ,4 ]
Korda, Rosemary [5 ]
Mills, Lucas [6 ]
Pearson, Sallie-Anne [2 ,3 ]
Pratt, Nicole [3 ,7 ]
Vajdic, Claire M. [3 ,8 ]
Welsh, Jennifer [5 ]
Macartney, Kristine [1 ,9 ]
机构
[1] Natl Ctr Immunisat Res & Surveillance, Westmead, Australia
[2] UNSW Sydney, Sch Populat Hlth, Kensington, Australia
[3] NHMRC Med Intelligence Ctr Res Excellence, Sydney, Australia
[4] Bond Univ, Inst Evidence Based Healthcare, Robina, Australia
[5] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, Australia
[6] Commonwealth Govt Australia, Dept Hlth & Aged Care, Canberra, Australia
[7] Univ South Australia, Qual Use Med & Pharm Res Ctr, Clin & Hlth Sci, Adelaide, Australia
[8] UNSW Sydney, Kirby Inst, Kensington, Australia
[9] Univ Sydney, Fac Med & Hlth, Camperdown, Australia
来源
关键词
COVID-19; Vaccine effectiveness; Mortality; Waning effectiveness; INFECTION; DURATION; OMICRON;
D O I
10.1016/j.lanwpc.2023.100928
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Few studies have examined effectiveness of COVID-19 vaccines against COVID-19 and all-cause mortality across different pandemic periods in 2022. Methods We used linked whole-of-population data from the 2021 Australian Census, Australian Immunisation Register, death registrations and other national datasets including migration data. Among 3.8 million adults aged 65+ years and >170,000 aged care residents, we used survival analysis to estimate vaccine effectiveness (VE) against COVID-19 specific mortality and all-cause mortality, by vaccine dose and time since receipt, adjusted for age, sex and other factors. We also estimated absolute COVID-19 mortality rates. Findings From January-May 2022 (Omicron BA.1/2), 3250 COVID-19 deaths occurred; from June-November (Omicron BA.4/5) 3185 COVID-19 deaths occurred. During January-May, VE of a 3rd COVID-19 vaccine dose within 3 months was 93% (95% CI 93-94%) whilst VE of a 2nd dose >6 months since receipt was 34% (26-42%). During June-November, VE of a 4th COVID-19 vaccine dose within 3 months was 84% (82-86%) whilst VE of a 3rd dose >6 months since receipt was 56% (50-62%). VE estimates for aged care residents were similar, but absolute risk reductions were substantially greater. During June-November 2022, for all-cause mortality, VE of a 4th dose within 3 months was 58% (56-59%) whilst VE of a 3rd dose >6 months since receipt was 19% (16-22%). Interpretations COVID-19 vaccination is highly effective against COVID-19 mortality among older adults although effectiveness wanes with time since the last dose. Our findings emphasise the importance of continuing to administer booster doses, particularly to those at highest risk.
引用
收藏
页数:13
相关论文
共 50 条
  • [11] Excess All-Cause Mortality During the COVID-19 Outbreak in Japan
    Yorifuji, Takashi
    Matsumoto, Naomi
    Takao, Soshi
    JOURNAL OF EPIDEMIOLOGY, 2021, 31 (01) : 90 - 92
  • [12] In COVID-19, tocilizumab reduces all-cause mortality at 28 d
    Fernando, Shannon M.
    Rochwerg, Bram
    ANNALS OF INTERNAL MEDICINE, 2021, 174 (06) : JC63 - JC63
  • [13] COVID-19 hospitalisations and all-cause mortality by risk group in Finland
    Summanen, Milla
    Kosunen, Mikko
    Kainu, Ville
    Cansel, Anniina
    Niskanen, Severi
    Nurmi, Lalli
    Leskelae, Riikka-Leena
    Isomeri, Outi
    PLOS ONE, 2023, 18 (05):
  • [14] IS TRANSAMINITIS AN INDEPENDENT RISK FACTOR FOR ALL-CAUSE MORTALITY IN COVID-19?
    Mughal, Mohsin
    Kaur, Ikwinder P.
    Kakadia, Mili
    Alhashemi, Reem
    Qudah, Hamzah A.
    Azad, Sarah
    Wang, Chang
    Mirza, Hasan M.
    Singh, Harjot
    Priya, Angi
    Eng, Margaret
    GASTROENTEROLOGY, 2021, 160 (06) : S851 - S851
  • [15] Predictors of All-Cause Mortality in Heart Transplant Recipients With COVID-19
    De Sirkar, Sovik
    Yu, Mingxi
    CIRCULATION, 2021, 144
  • [16] Platelet Activation is Associated With All-cause Mortality in Patients With Covid-19
    Barrett, Tessa J.
    Lee, Angela
    Xia, Yuhe
    Lin, Lawrence
    Black, Margaret
    Cotzia, Paolo
    Hochman, Judith S.
    Berger, Jeffrey S.
    CIRCULATION, 2020, 142
  • [17] Estimation of Excess All-Cause Mortality Due to COVID-19 in Thailand
    Wilasang, Chaiwat
    Modchang, Charin
    Lincharoen, Thanchanok
    Chadsuthi, Sudarat
    TROPICAL MEDICINE AND INFECTIOUS DISEASE, 2022, 7 (07)
  • [18] Anticoagulants and all-cause mortality among hospitalized COVID-19 patients
    Liang, Caihua
    Zhou, Li
    Doherty, Michael C.
    Gately, Robert V.
    Ogilvie, Rachel P.
    Chomistek, Andrea K.
    Wang, Florence
    Seeger, John D.
    Franklin, Jessica
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 78 - 78
  • [19] Impact of influenza vaccination on GP-diagnosed COVID-19 and all-cause mortality: a Dutch cohort study
    van Laak, Arjan
    Verhees, Ruud
    Knottnerus, J. Andre
    Hooiveld, Mariette
    Winkens, Bjorn
    Dinant, Geert-Jan
    BMJ OPEN, 2022, 12 (09):
  • [20] Association between influenza vaccination and hospitalisation or all-cause mortality in people with COVID-19: a retrospective cohort study
    Wilcox, Christopher R.
    Islam, Nazrul
    Dambha-Miller, Hajira
    BMJ OPEN RESPIRATORY RESEARCH, 2021, 8 (01)